Skip to main content
Caplight Logo









Glycotope GmbH

Glycotope GmbH

Private

Last Round

VC Round

Mar 11, 2014

Total Funding Raised

$57.1M

Company Overview

Glycotope GmbH operates in Healthcare & Life Sciences and is based in Berlin. Its latest recorded funding round was a VC Round in March 2014.

Glycotope GmbH is a biotechnology company that develops tumor-specific monoclonal antibodies and glycobiology-based therapeutics for the treatment of various cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Glycotope GmbH Comparables

Compare Glycotope GmbH with similar companies based on industry and business-model similarity.

Glycotope GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Danaher
80%
Kyowa Kirin
76%
Merck & Co., Inc.
76%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Glycotope GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 11, 2014
Series ANov 1, 2007
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Glycotope GmbH Investors

Notable investors and investment history

Glycotope GmbH investors
InvestorRounds
ELSA Eckert Life Science AcceleratorSeries A, VC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 11, 2014

    $76.2M raised from ELSA Eckert Life Science Accelerator.

Book a demo to see all signals

For institutional investors. Book with your work email.

Glycotope GmbH Filings

Explore SEC and related filing metadata, where available.

Glycotope GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Glycotope GmbH's valuation, stock price, and market status.

Is Glycotope GmbH a public or private company?

Glycotope GmbH is a private company.

What is the current stock price of Glycotope GmbH?

Glycotope GmbH is a private company, so its shares have no public market price. Caplight tracks Glycotope GmbH's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Glycotope GmbH worth (valuation)?

Valuation information for Glycotope GmbH is not publicly available.

Can I buy Glycotope GmbH stock?

Glycotope GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Glycotope GmbH's last funding round?

Glycotope GmbH's most recent funding round was VC Round on March 11, 2014.

Who are the main investors in Glycotope GmbH?

Key investors in Glycotope GmbH include ELSA Eckert Life Science Accelerator.

Will Glycotope GmbH IPO soon?

No public IPO plans have been announced for Glycotope GmbH.

How can I track Glycotope GmbH secondary market activity?

Caplight tracks bids, offers, and trades in Glycotope GmbH's shares on secondary markets.

Firmographic Details

HeadquartersBerlin
Year Founded2001
Last FundingMar 11, 2014

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?